Zalevsky Jonathan 4
4 · NEKTAR THERAPEUTICS · Filed Sep 8, 2025
Insider Transaction Report
Form 4
Zalevsky Jonathan
Chief R&D Officer
Transactions
- Sale
Common Stock
2025-09-04$32.43/sh−793$25,717→ 18,390 total - Sale
Common Stock
2025-09-04$33.60/sh−432$14,515→ 17,958 total - Sale
Common Stock
2025-09-04$34.41/sh−189$6,503→ 17,769 total - Sale
Common Stock
2025-09-04$35.69/sh−307$10,957→ 17,462 total
Footnotes (5)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $32.08 to $33.02 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- [F3]This transaction was executed in multiple trades at prices ranging from $33.08 to $34.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- [F4]This transaction was executed in multiple trades at prices ranging from $34.09 to $34.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- [F5]This transaction was executed in multiple trades at prices ranging from $35.48 to $36.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.